Basit öğe kaydını göster

Clodronic acid in the treatment of postmenopausal osteoporosis

dc.contributor.authorBoztepe, Harika
dc.contributor.authorYarman, Sema
dc.contributor.authorAlagol, Faruk
dc.contributor.authorTanakol, Refik
dc.contributor.authorBayraktaroglu, Taner
dc.date.accessioned2021-03-06T08:03:24Z
dc.date.available2021-03-06T08:03:24Z
dc.date.issued2007
dc.identifier.citationTanakol R., Yarman S., Bayraktaroglu T., Boztepe H., Alagol F., "Clodronic acid in the treatment of postmenopausal osteoporosis", CLINICAL DRUG INVESTIGATION, cilt.27, ss.419-433, 2007
dc.identifier.issn1173-2563
dc.identifier.otherav_df22b7d7-5070-4e14-977a-5b7f3a6d9ac2
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/146990
dc.identifier.urihttps://doi.org/10.2165/00044011-200727060-00005
dc.description.abstractBackground: Clodronic acid, a first-generation bisphosphonate, has been successfully used in the treatment of high bone turnover states, Paget's disease and osteolytic bone metastases. However, controversies remain over its optimal dosage and method of administration in the treatment of postmenopausal osteoporosis. In this study we aimed to evaluate the effect of clodronic acid treatment for 3 years on bone mineral density (BMD) in women with postmenopausal osteoporosis.
dc.language.isoeng
dc.subjectEczacılık
dc.subjectTemel Bilimler
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleClodronic acid in the treatment of postmenopausal osteoporosis
dc.typeMakale
dc.relation.journalCLINICAL DRUG INVESTIGATION
dc.contributor.department, ,
dc.identifier.volume27
dc.identifier.issue6
dc.identifier.startpage419
dc.identifier.endpage433
dc.contributor.firstauthorID181055


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster